NCT03035799

Brief Summary

This pilot study proposes to gain a better understanding of the health benefits of the popular "paleo-diet" in patients with irritable bowel syndrome (IBS) and explore underlying mechanisms of benefit.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 30, 2017

Completed
1.2 years until next milestone

Study Start

First participant enrolled

April 24, 2018

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2020

Completed
Last Updated

May 7, 2020

Status Verified

May 1, 2020

Enrollment Period

1.9 years

First QC Date

January 18, 2017

Last Update Submit

May 5, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Vitality

    Vitality as measured on the vitality subscale of the short form health survey (SF36). This instrument assesses vitality (energy level and fatigue) and is a subscale of SF36, a general health survey designed for use in clinical practice and research, health policy evaluation and general population surveys. The Vitality Subscale score is determined by responses to 4 items: Did you feel full of life? Did you have a lot of energy? Did you feel worn out? Did you feel tired? The lower the score the more disability. The higher the score the less disability.

    The change between baseline and 4 weeks (post-intervention).

Secondary Outcomes (7)

  • Anxiety

    The change between baseline and 4 weeks (post-intervention).

  • Depression

    The change between baseline and 4 weeks (post-intervention).

  • Activity level

    The change between baseline and 4 weeks (post-intervention).

  • Gastrointestinal symptoms

    The change between baseline and 4 weeks (post-intervention).

  • Visceral sensitivity

    The change between baseline and 4 weeks (post-intervention).

  • +2 more secondary outcomes

Other Outcomes (8)

  • Intestinal permeability

    The change between baseline and 4 weeks (post-intervention).

  • Change in inflammatory markers

    The change between baseline and 4 weeks (post-intervention).

  • Change in stool metabolomics

    The change between baseline and 4 weeks (post-intervention).

  • +5 more other outcomes

Study Arms (2)

Paleolithic Diet

EXPERIMENTAL

Paleolithic Diet

Other: Paleolithic diet

General Healthful Diet

ACTIVE COMPARATOR

General Healthful Diet

Other: General Healthful Diet

Interventions

Paleolithic diet

Paleolithic Diet

General Healthful Diet

General Healthful Diet

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with mild to moderate Irritable Bowel Syndrome (IBS) and mild to moderate anxiety or depression
  • Other causes of bowel symptoms excluded to the satisfaction of the Study Team
  • Age at least 18 years at initial screening visit
  • Patients who are able to sign and understand the study's informed consent form
  • Patients able to complete all screening evaluations and procedures

You may not qualify if:

  • Patients in inpatient hospital care
  • Severe or refractory bowel or psychological symptoms
  • Current consumption of a Paleolithic diet
  • Known Celiac disease
  • Uncontrolled thyroid disease as indicated by an abnormal thyroid stimulating hormone (TSH) level
  • Uncontrolled diabetes as indicated by a HbA1c equal to 6.5 or greater
  • Patients unable to speak English
  • Inability to obtain informed consent
  • Pregnant or nursing women
  • Any condition, which in the opinion of the investigator, would interfere with study requirements

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins University

Baltimore, Maryland, 21287, United States

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome

Interventions

Diet, Paleolithic

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Diet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Pankaj Pasricha, MD

    Johns Hopkins University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 18, 2017

First Posted

January 30, 2017

Study Start

April 24, 2018

Primary Completion

April 1, 2020

Study Completion

April 1, 2020

Last Updated

May 7, 2020

Record last verified: 2020-05

Locations